AbbVie Picks Up Dong-A Candidate As It Makes Immuno-Onc Inroads

Dong-A ST has scored a major early success in its inroads into cancer R&D through a sizable immuno-oncology deal with AbbVie, which also underscores the US firm’s push to expand its assets in the area.

businessman and businesswoman are shaking hands and exchanging folder after agreement was reached

Dong-A ST Co. Ltd. has reached a co-development and licensing agreement with AbbVie Biotechnology, a subsidiary of AbbVie Inc., for the South Korean pharma firm's early stage Mer tyrosine kinase inhibitor candidate, in an alliance potentially worth up to $525m plus sales royalties.

Under the deal, Dong-A ST and AbbVie will jointly develop the still preclinical stage molecule until submission of an IND...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip